AMT-676 / Multitude Therap - LARVOL DELTA

A phase 1, first-in-human study of AMT-676, an anti-CDH17 antibody-drug conjugate, in patients with advanced gastrointestinal tumors. (ASCO 2025) - P1 | "The study is actively enrolling participants for the dose escalation phase. Cohorts 1-4 have been completed DLT evaluation and enrollment of cohort 5 began in December 2024."

Clinical • Metastases • P1 data • Biliary Cancer • Cholangiocarcinoma • Endocrine Cancer • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • CDH17

AMT-676 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Multitude Therapeutics Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

AMT-676 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Multitude Therapeutics Inc.

Metastases • New P1 trial • Oncology • Solid Tumor